Table 2. Analysis of diagnostic intervals between cohorts 2001–2002 and 2007–2008 in 15 cancer sites by first presentation of any cancer symptom.
|
Diagnostic interval (days) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
|
|
IQR |
|
|
|
|
95% CI |
|
||
| Cancer site | Cohort | N | Median | 25th percentile | 75th percentile | 90th percentile | Mean | s.d. | Mean differencea | Lower | Upper | P-value |
| Colorectal | Cohort 1 (2001–2002) | 1947 | 100 | 42 | 201 | 298 | 129.6 | 103.1 | −9.0 | −14.8 | −3.2 | 0.002 |
| |
Cohort 2 (2007–2008) |
2962 |
80 |
37 |
187 |
298 |
120.6 |
103.9 |
|
|
|
|
| Lung | Cohort 1 (2001–2002) | 1816 | 114 | 48 | 238 | 318 | 144.8 | 110.7 | 2.4 | −4.1 | 8.8 | 0.47 |
| |
Cohort 2 (2007–2008) |
2851 |
112 |
45 |
251 |
325 |
147.2 |
114.0 |
|
|
|
|
| Breast | Cohort 1 (2001–2002) | 813 | 31 | 14 | 72 | 210 | 65.5 | 84.7 | −3.5 | −11.5 | 4.1 | 0.37 |
| |
Cohort 2 (2007–2008) |
996 |
26 |
15 |
61 |
203 |
62.0 |
84.8 |
|
|
|
|
| Pancreatic | Cohort 1 (2001–2002) | 429 | 67 | 29 | 163 | 291 | 108.3 | 103.1 | −12.6 | −24.6 | 0.2 | 0.04 |
| |
Cohort 2 (2007–2008) |
563 |
56 |
25 |
142 |
250 |
95.7 |
94.1 |
|
|
|
|
| Oesophageal | Cohort 1 (2001–2002) | 672 | 72 | 31 | 189 | 304 | 116.9 | 107.4 | −13.1 | −24.1 | −3.0 | 0.006 |
| |
Cohort 2 (2007–2008) |
930 |
58 |
28 |
154 |
283 |
103.7 |
102.4 |
|
|
|
|
| Gastric | Cohort 1 (2001–2002) | 535 | 101 | 43 | 220 | 314 | 135.5 | 108.4 | −6.0 | −18.7 | 5.5 | 0.33 |
| |
Cohort 2 (2007–2008) |
761 |
89 |
36 |
206 |
315 |
129.5 |
109.5 |
|
|
|
|
| Endometrial | Cohort 1 (2001–2002) | 232 | 85 | 43 | 154 | 240 | 109.6 | 86.8 | −8.3 | −21.8 | 5.3 | 0.22 |
| |
Cohort 2 (2007–2008) |
515 |
70 |
36 |
140 |
238 |
101.3 |
86.0 |
|
|
|
|
| Cervix | Cohort 1 (2001–2002) | 77 | 75 | 37 | 162 | 295 | 110.2 | 96.6 | −13.7 | −41.8 | 14.1 | 0.33 |
| |
Cohort 2 (2007–2008) |
93 |
66 |
30 |
113 |
232 |
96.5 |
90.5 |
|
|
|
|
| Kidney | Cohort 1 (2001–2002) | 120 | 120 | 50 | 211 | 294 | 136.2 | 101.0 | −20.4 | −41.5 | 0.5 | 0.05 |
| |
Cohort 2 (2007–2008) |
338 |
80 |
39 |
169 |
280 |
115.8 |
98.0 |
|
|
|
|
| Bladder | Cohort 1 (2001–2002) | 664 | 107 | 52 | 214 | 300 | 134.4 | 101.0 | −16.4 | −26.5 | −6.6 | <0.001 |
| |
Cohort 2 (2007–2008) |
1018 |
81 |
38 |
178 |
290 |
118.1 |
102.8 |
|
|
|
|
| Testicular | Cohort 1 (2001–2002) | 34 | 53 | 25 | 104 | 190 | 75.6 | 68.7 | −19.2 | −45.1 | 5.7 | 0.14 |
| |
Cohort 2 (2007–2008) |
69 |
44 |
21 |
72 |
113 |
56.5 |
53.0 |
|
|
|
|
| Head and Neck | Cohort 1 (2001–2002) | 155 | 113 | 59 | 212 | 322 | 141.7 | 107.1 | −21.2 | −41.6 | −0.2 | 0.04 |
| |
Cohort 2 (2007–2008) |
216 |
87 |
50 |
177 |
272 |
120.4 |
92.9 |
|
|
|
|
| Lymphoma | Cohort 1 (2001–2002) | 288 | 109 | 50 | 229 | 330 | 143.2 | 110.8 | −11.1 | −28.5 | 4.3 | 0.18 |
| |
Cohort 2 (2007–2008) |
458 |
99 |
44 |
218 |
302 |
132.1 |
104.7 |
|
|
|
|
| Leukaemia | Cohort 1 (2001–2002) | 178 | 88 | 27 | 199 | 324 | 125.3 | 112.7 | 3.0 | −20.0 | 25.6 | 0.80 |
| |
Cohort 2 (2007–2008) |
243 |
92 |
24 |
230 |
311 |
128.3 |
115.0 |
|
|
|
|
| Myeloma | Cohort 1 (2001–2002) | 221 | 144 | 56 | 264 | 325 | 161.5 | 112.3 | 6.8 | −12.4 | 26.4 | 0.50 |
| |
Cohort 2 (2007–2008) |
341 |
156 |
59 |
273 |
336 |
168.3 |
114.7 |
|
|
|
|
| Pooled | Cohort 1 (2001–2002) | 8181 | 90 | 36 | 202 | 304 | 125.8 | 106.5 | −5.4 | −8.5 | −2.4 | <0.001 |
| Cohort 2 (2007–2008) | 12 354 | 77 | 34 | 195 | 302 | 120.4 | 106.8 | |||||
a
‘−'sign denotes a reduction in diagnostic intervals from Cohort 2001–2002 to Cohort 2007–2008.